• Skip to main content

DistilINFO LifeSciences

Weekly round up from Life Sciences Industry.

  • Publications
    • Home
    • DistilINFO HealthPlan
    • DistilINFO HospitalIT
    • DistilINFO IT
    • DistilINFO Retail
    • DistilINFO POPHealth
    • DistilINFO Ageing
    • DistilINFO Life Sciences
    • DistilINFO GovHealth
    • DistilINFO EHS
    • DistilINFO HealthIndia
    • Subscribe
    • Submit Article
    • Advertise
    • Newsletters

Philips and Merck Partner to Develop Personalised Fertility Treatment

Share:

February 2, 2021

Remote patient monitoring, cloud-based platform services and AI-enabled ultrasound diagnoses will be used to improve outcomes in fertility treatment.

Netherlands-based global health technology company, Royal Philips has announced a multi-year partnership with US science and technology company, Merck to develop digital solutions for personalised fertility treatment.

WHY IT MATTERS

According to the National Health Service, roughly one in seven couples in the UK will have trouble conceiving.

The platform will leverage advanced informatics and mobile, AI-enabled ultrasound diagnostics, to better inform patients and clinicians about the choice and timing of fertility treatment to maximise the chances of conception.

THE LARGER CONTEXT

Want to publish your own articles on DistilINFO Publications?

Send us an email, we will get in touch with you.

Investors have gained an increased interest for femtech and fertility apps recently as remote monitoring models have picked up and proved invaluable during the pandemic.

An example of this growth in interest is the UK-based digital fertility employee benefits company Fertifa achieved the closing of its £1 million financing round last year.

Virtual fertility clinic Apricity launched an online fertility predictor tool designed to predict a woman’s chances of conceiving naturally based on information input on their lifestyle choices.

ON THE RECORD

Jeroen Tas, chief innovation and strategy officer at Royal Philips said: “At Philips we are leading digital transformation in healthcare, with a portfolio that includes solutions for both professionals and consumers to support parents-to-be through pregnancy and the first years of their baby’s life.

“The journey for aspiring parents is sometimes a difficult one, and by collaborating with Merck, a world leader in fertility treatment, we aim to develop integrated digital solutions that improve the patient experience and can ultimately have a positive impact on health outcomes. This partnership builds on our expertise in maternal and fetal monitoring, our Pregnancy+ and Baby+ consumer engagement apps, our leading ultrasound solutions and our HealthSuite Cloud/AI platform.”

Michelangelo Canzoneri, global head of digital and data, Healthcare at Merck said: “We believe that the future of IVF will be unlocked through digital health technologies that empower professionals and patients to be better connected.”

Jan Kirsten, head of global business franchise for fertility at Merck added: “With Philips, we have a partner that shares our belief in the potential of digital health to improve the patient experience, bringing a wealth of experience in connected care to our offering. Together, this collaboration will push our two companies to think beyond tomorrow and discover new solutions that can empower people to realise their dreams of parenthood.”

Source: Mobihealth News

Coffee with DistilINFO's Morning Updates...

Sign up for DistilINFO e-Newsletters.

Just a little bit more about you...
PROCEED
Choose Lists
BACK

Related Stories

  • Harmony Biosciences Completes Acquisition of Zynerba Pharmaceuticals and Expands PipelineHarmony Biosciences Completes Acquisition of Zynerba Pharmaceuticals and Expands Pipeline
  • Gracell Biotech | AstraZeneca Acquisition Fuels Future InnovationsGracell Biotech | AstraZeneca Acquisition Fuels Future Innovations
  • How Blockchain can disrupt the Healthcare IndustryHow Blockchain can disrupt the Healthcare Industry
  • Boehringer Ingelheim Collaborates with Proxygen to Explore Molecular Glue Degraders – a Novel Approach to Fight CancerBoehringer Ingelheim Collaborates with Proxygen to Explore Molecular Glue Degraders – a Novel Approach to Fight Cancer
  • Bausch Health’s Bausch + Lomb Announces Launch of Proposed Financing for Acquisition of XIIDRA(R)Bausch Health’s Bausch + Lomb Announces Launch of Proposed Financing for Acquisition of XIIDRA(R)
  • Flare Capital Partners Closes Second Fund With $255MFlare Capital Partners Closes Second Fund With $255M
  • Legato Healthcare Marketing Acquires Fresh Digital MarketingLegato Healthcare Marketing Acquires Fresh Digital Marketing
  • DarioHealth Acquires Twill Boosting Revenue, Expediting ProfitabilityDarioHealth Acquires Twill Boosting Revenue, Expediting Profitability

Trending This Week

Sorry. No data so far.

About Us

DistilINFO is media company that publishes Industry news, views and Interviews. We distil the information for you – saving time and keeping you up to date on your interest areas.

More About Us

Follow Us


Useful Links

  • Subscribe
  • Contact
  • Advertise
  • Privacy Policy
  • Terms of Service
  • Feedback

All Publications

  • DistilINFO HealthPlan Advisory
  • DistilINFO HospitalIT Advisory
  • DistilINFO IT Advisory
  • DistilINFO Retail Advisory
  • DistilINFO POPHealth Advisory
  • DistilINFO Ageing Advisory
  • DistilINFO Life Sciences Advisory
  • DistilINFO GovHealth Advisory
  • DistilINFO EHS Advisory
  • DistilINFO HealthIndia Advisory

© DistilINFO Publications